Business
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The findin
About this update from Eisai Co., Ltd.
[{"type":"text","content":"TOKYO and CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI®), an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The findings represent the results from a large-scale clinical study demonstrating, for the first time, that binding of lecanemab to PF can be measured in CSF, enabling further understanding of how lecanemab slows Alzheimer's disease (AD) progression.","length":831,"tagName":"p"},{"type":"image","alt":"Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)","displaySize":"","headline":null,"caption":"Eisai logo and Biogen logo (PRNewsfoto/Eisai Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0o85llr4k4YPB6fanxtHPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/723010/Eisai_Logo_and_Biogen_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"AD is a progressive, relentless disease with Aβ and tau as hallmarks. It is caused by a continuous underlying neurotoxic process driven by PF that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3 Only LEQEMBI fights AD in two ways: targeting both protofibrils and amyloid plaque, which can impact tau downstream.","length":346,"tagName":"p"},{"type":"text","content":"In a CSF sub-cohort (n=410) of the Phase III Clarity AD study, total PF concentration in CSF was quantified using an ultrasensitive assay. Changes from baseline (pre-treatment) for the placebo group (natural course) and the lecanemab group were compared, and associations between PF changes and neurodegeneration biomarkers were analyzed.","length":348,"tagName":"p"},{"...